TY - JOUR
T1 - Proteomic Analysis of Complement Proteins in Membranous Nephropathy
AU - Ravindran, Aishwarya
AU - Madden, Benjamin
AU - Charlesworth, M. Cristine
AU - Sharma, Rishi
AU - Sethi, Amit
AU - Debiec, Hanna
AU - Cattran, Daniel
AU - Fervenza, Fernando C.
AU - Smith, Richard J.
AU - Ronco, Pierre
AU - Sethi, Sanjeev
N1 - Funding Information:
We thank the Mayo Clinic Genome Facility-Proteomics Core (a shared resource of the Mayo Clinic Cancer Center [NCI P30 CA15083], Department of Laboratory Medicine and Pathology and the Pathology Research Core, Mayo Clinic). PR is a recipient of European Research Council ERC-2012-ADG_20120314 grant 322947 and 7th Framework Programme of the European Community contract 2012-305608 (European Consortium for High-Throughput Research in Rare Kidney Diseases), and the National Research Agency grant MNaims (ANR-17- CE17-0012-01). Research is supported in part by the US National Institutes of Health grant R01 DK110023 to RJS.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/5
Y1 - 2020/5
N2 - Introduction: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in Caucasian adults. Phospholipase A2 receptor (PLA2R)– and exostosin 1 (EXT1)/exostosin 2 (EXT2)–associated MN represent the most common primary and secondary forms of MN. The complement profile using a proteomics approach has not been studied in these 2 common forms of MN. Methods: We used laser microdissection and mass spectrometry (MS/MS) to dissect glomeruli and identify glomerular complement proteins in PLA2R-associated (n = 7), EXT1/EXT2-associated MN (n = 21), and 11 control cases (time 0 transplant biopsies). Results: MS/MS identified high total spectral counts for PLA2R and EXT1/EXT2 in corresponding cases of PLA2R- and EXT1/EXT2-positive MN. Both PLA2R- and EXT1/EXT2-associated MN had high spectral counts of complement proteins C3, C4, C5, C6, C7, C8, and C9. Complement protein C1 was present in low spectral counts in EXT1/EXT2-associated MN. Regulators of complement activation that were detected in MN included higher spectral counts of FH, FHR-1, FHR-5, clusterin, vitronectin and lower spectral counts of FHR-3, FHR-4, and CD59. Low spectral counts of FB and properdin, key components of the alternative pathway, also were detected. IgG4 and IgG1 were the most abundant IgG subclasses in PLA2R- and EXT1/EXT2-associated MN. Lower spectral counts for C3, C4, and C5 were detected in control cases when compared with MN. Conclusion: Significant complement activation is present in MN as evidenced by large spectral counts of complement proteins from C3- and C4-based pathways, including regulatory proteins of complement pathways. These data suggest that anticomplement drugs may be effective in treatment for MN.
AB - Introduction: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in Caucasian adults. Phospholipase A2 receptor (PLA2R)– and exostosin 1 (EXT1)/exostosin 2 (EXT2)–associated MN represent the most common primary and secondary forms of MN. The complement profile using a proteomics approach has not been studied in these 2 common forms of MN. Methods: We used laser microdissection and mass spectrometry (MS/MS) to dissect glomeruli and identify glomerular complement proteins in PLA2R-associated (n = 7), EXT1/EXT2-associated MN (n = 21), and 11 control cases (time 0 transplant biopsies). Results: MS/MS identified high total spectral counts for PLA2R and EXT1/EXT2 in corresponding cases of PLA2R- and EXT1/EXT2-positive MN. Both PLA2R- and EXT1/EXT2-associated MN had high spectral counts of complement proteins C3, C4, C5, C6, C7, C8, and C9. Complement protein C1 was present in low spectral counts in EXT1/EXT2-associated MN. Regulators of complement activation that were detected in MN included higher spectral counts of FH, FHR-1, FHR-5, clusterin, vitronectin and lower spectral counts of FHR-3, FHR-4, and CD59. Low spectral counts of FB and properdin, key components of the alternative pathway, also were detected. IgG4 and IgG1 were the most abundant IgG subclasses in PLA2R- and EXT1/EXT2-associated MN. Lower spectral counts for C3, C4, and C5 were detected in control cases when compared with MN. Conclusion: Significant complement activation is present in MN as evidenced by large spectral counts of complement proteins from C3- and C4-based pathways, including regulatory proteins of complement pathways. These data suggest that anticomplement drugs may be effective in treatment for MN.
KW - complement
KW - laser microdissection
KW - mass spectrometry
KW - membranous nephropathy
UR - http://www.scopus.com/inward/record.url?scp=85081644995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081644995&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2020.01.018
DO - 10.1016/j.ekir.2020.01.018
M3 - Article
AN - SCOPUS:85081644995
SN - 2468-0249
VL - 5
SP - 618
EP - 626
JO - Kidney International Reports
JF - Kidney International Reports
IS - 5
ER -